The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

  • Rowinsky E
  • Donehower R
  • 34

    Readers

    Mendeley users who have this article in their library.
  • 287

    Citations

    Citations of this article.

Abstract

Although there has been a rapid expansion of the number of classes of compounds with antineoplastic activity, few have played a more vital role in the curative and palliative treatment of cancers than the antimicrotubule agents. Although the vinca alkaloids have been the only subclass of antimicrotubule agents that have had broad experimental and clinical applications in oncologic therapeutics over the last several decades, the taxanes, led by the prototypic agent taxol, are emerging as another very active class of antimicrotubule agents. After briefly reviewing the mechanisms of antineoplastic action and resistance, this article comprehensively reviews the clinical pharmacology, therapeutic applications, and clinical toxicities of selected antimicrotubule agents. © 1992.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Eric K. Rowinsky

  • Ross C. Donehower

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free